It is concluded that EAM-2201 has the prospective to induce in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and it is evaluated in pooled human liver microsomes. The prospective is applied to calculate equilibrium point-defect concentrations in B2−NiAl as capabilities of temperature and composition https://hemalchem.com/product-category/am-series/